|
|
|
 |
Forum Panel |
[story]
NYfXjYeOqrkyq |
Will I have to work on Saturdays? http://egotastic.in.net egotasticallstars
TB is always treated with three or more meds to reduce emergence of drug resistance, but preclinical studies performed independently by Sequella and Pfizer show SQ109 and sutezolid to each have activity as single agents, and promising additional activity when used in combination. Privately-held Sequella added that reports estimate a $400-$500 million global peak sales market for a drug to treat MDR-TB, some 5% of TB cases worldwide.
|
 |
 Author: Brain
Date: 5/27/2019 |
 Response
to this message |
|
